Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line

Asimov, the synthetic biology company advancing the design and manufacture of therapeutics, today announced a licensing agreement for its CHO Edge System with RevOpsis Therapeutics ("RevOpsis"), a next-generation biopharmaceutical company spearheading innovation of multispecific biologics in ophthalmic therapies. This agreement follows a successful cell line development campaign with Asimov's CHO Edge System for the lead RevOpsis asset, RO-104.

Under the terms of the agreement, RevOpsis will integrate the CHO Edge System in the development and commercialization of its first-in-class fully modular tri-specific biologic, RO-104, for the treatment of retinal vascular diseases. RO-104 is designed to address all three clinically validated dominant angiogenic pathways (VEGF-A, VEGF-C, Ang-2) implicated in retinal vascular disease progression, including neovascular AMD and diabetic macular edema. RevOpsis has made significant progress with clinical progression of RO-104 supporting the initiation of IND-enabling studies beginning in January 2025

The CHO Edge System incorporates a GMP-banked CHO-K1 glutamine synthetase (GS) knockout host - or alternatively a GS-Fut8 double knockout for producing afucosylated antibodies - along with a hyperactive transposase, a library of over one thousand characterized genetic parts for vector design, and advanced AI and biophysics models. The system reliably generates stable cell lines with high titer and exceptional product quality, enabling optimization of the expression vector and bioreactor processes across various biologics modalities.

Asimov's CHO Edge System continues to gain rapid adoption since its launch last year. We are delighted that RevOpsis is joining the growing set of partners that are putting their trust in our platform. CHO Edge will form the cornerstone of their bioproduction process for an impactful therapeutic that will serve unmet needs in a growing patient population. We look forward to supporting their biologic development as they progress through clinical trials."

Alec Nielsen, co-founder and CEO, Asimov

Ramanath Bhandari, RevOpsis co-founder and CEO, commented: "RevOpsis is committed to the rapid discovery and development of novel multispecific therapies utilizing our modular RevMod™ Platform that consists of fully-human libraries. Asimov's CHO Edge System has exhibited great performance and will underpin the development and commercialization of our lead clinical asset RO-104 for the treatment of retinal vascular disease progression, including neovascular age-related macular degeneration."​​​​​​​

Source:

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Asimov. (2024, November 25). Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line. News-Medical. Retrieved on December 04, 2024 from https://www.news-medical.net/news/20241125/Asimov-and-RevOpsis-Therapeutics-sign-licensing-agreement-for-high-titer-multispecific-expressing-cell-line.aspx.

  • MLA

    Asimov. "Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line". News-Medical. 04 December 2024. <https://www.news-medical.net/news/20241125/Asimov-and-RevOpsis-Therapeutics-sign-licensing-agreement-for-high-titer-multispecific-expressing-cell-line.aspx>.

  • Chicago

    Asimov. "Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line". News-Medical. https://www.news-medical.net/news/20241125/Asimov-and-RevOpsis-Therapeutics-sign-licensing-agreement-for-high-titer-multispecific-expressing-cell-line.aspx. (accessed December 04, 2024).

  • Harvard

    Asimov. 2024. Asimov and RevOpsis Therapeutics sign licensing agreement for high titer multispecific-expressing cell line. News-Medical, viewed 04 December 2024, https://www.news-medical.net/news/20241125/Asimov-and-RevOpsis-Therapeutics-sign-licensing-agreement-for-high-titer-multispecific-expressing-cell-line.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Comments are closed

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.